Table 5

Change in Average MIT From Baseline to Month 12 by Presence or Absence of BPAR ≥2R or Rejection With HDC

Change in Average MIT (mm)
Patient subgroupEverolimus 1.5 mg
(n = 88)
MMF
(n = 101)
p Value
With BPAR ≥2R/ rejections with HDCn = 16
0.04 ± 0.06
n = 26
0.06 ± 0.09
0.423
Without BPAR ≥2R/ rejections with HDCn = 72
0.02 ± 0.05
n = 75
0.071 ± 0.12
<0.001

Values are mean ± SD. p = 0.348 for the interaction between change in average MIT and rejection status at Month 12. Bold values indicate p<0.05.

BPAR = biopsy proven acute rejection; HDC = hemodynamic compromise; MIT = maximal intimal thickness; MMF = mycophenolate mofetil.